EH 3_2015

www.healthcare-in-europe.com 19RADIOLOGY MRI versus pathologyhip’ ‘We need more feedback’ view nostics Report: Karoline Laarmann What you see is what you get - unfor- tunately, this doesn’t always apply in cancer imaging. Why is it that something which looks conspicuous on an image later turns out not to be a tumour? Why, on the other hand, are things overlooked that later turn out to be cancer? Pathological findings are extremely important to help improve diagnostic precision in radiology. Both disciplines therefore engage in an intensive dialogue at German Congress of Radiology in May. One focus of this interdisciplinary exchange was the diagnosis of pros- tate cancer. In this field, Dr Matthias C Röthke, Senior Consultant at the Department of Radiology at the German Cancer Research Centre, in Heidelberg, is among the leading imaging experts. Currently, the procedure of choice for prostate imaging is multipar- ametric MRI, which supplements morphological image data with functional parameters. ‘The term functional basically refers to the diffusion behaviour in the tissue,’ Röthke explains. ‘Tumours are char- acterised by a high cell division rate. When you look at them under the microscope you see that the tissue consists of many large cell nuclei and little cytoplasm. ‘Accordingly, measurements car- ried out with diffusion weighted MRI show that the water molecules move around less freely in this type of tissue.’ A further, functional cri- terion, which is examined with the help of contrast media dynamics, is perfusion behaviour, because the perfusion patterns of tumours differ from those in healthy tissue. If all available radiological meas- uring procedures are combined, this results in a sensitivity of 90%. ‘The diagnostic precision obviously also depends on the examiner,’ the radiologist admits. ‘If a procedure is carried out by an expert, the rate is higher than that achieved by a less experienced examiner. Unfortunately, there are as yet no certified radiologists who are spe- cifically trained in prostate imaging, unlike those specialising in mam- mography. The referring urologists are making increasingly frequent demands for this further training because they are looking for reliable quality standards for prostate MRI procedures carried out by radiolo- gists.’ Dr Röthke believes that organi- sational structures similar to those in place for the diagnosis of breast cancer are absolutely essential. This starts with the biopsy. The prostate is the only organ from which tis- sue samples are taken at random – with the help of transrectal ultra- sound to assist with orientation – as part of the primary diagnosis. With all other organs, suspected lesions are precisely targeted under image guidance these days. ‘A prostate MRI should at least be carried out in patients whose primary, ultrasound- guided ten or twelve stent biopsy was negative, but whose PSA level continues to rise so that a possible lesion can be precisely targeted with a repeat biopsy,’ Röthke says. His demands go beyond that. ‘What we need for prostate cancer are interdisciplinary case confer- ences as we know them from the field of breast cancer diagnostics. This would give us a quality forum where radiologists, urologists, radio- therapists and pathologists could exchange and update their knowl- edge. Such feedback discussions are currently usually carried out on an occasional and informal basis, whenever it fits into clinical routine. However, we need an official frame- work to achieve comprehensive and competent care for the imaging of prostate cancer.’ information gained from images and pathologists could present their diagnostic findings gained from tis- sue analyses. ‘Both disciplines would benefit from this, but most importantly so would the patient.’ Senior consultant Matthias C Röthke MD, Dipl.-Kfm. is primarily responsible for Urogenital Imaging within the Radiology Department at the German Cancer Research Centre (DKFZ) in Heidelberg. He studied medicine in Erlangen and Freiburg, completed his specialist training in Diagnostic Radiology at the University Hospital Tübingen and, in 2010, became a consultant at the DKFZ. Along with his membership of the Working Group for Uroradiology and Urogenital Diagnostics in the DRG, he is also a member of the Working Group for Prostate Imaging at the European Society of Urogenital Radiology (ESUR). Comparison MRI - Pathology: On the left morphological T2-weighted MRI and on the right the corresponding histological specimen. The areas with prostate cancer are framed on both sides. On the left two additional microlesions < 1mm are marked that cannot be detected with morphological imaging, but which can be classified as clinically not relevant cancer Glen Kristiansen was Professor for Molecular Tumour Pathology and Senior Consultant of the Pathology Department, University of Zurich for four years before he took over the directorship of the Institute for Pathology at Bonn University Hospital in May 2011. The pathologist is a Member of the Board and European Representative of the International Society of Urological Pathology (ISUP) and of the Advisory Board at the European Network for Uropathology (ENUP). He is also a member of the WHO Panel of Experts on Urological Pathology and of numerous other national and international specialist pathology- and cancer research associations. Source:Prof.Dr.GlenKristiansen Source:Prof.Dr.GlenKristiansen

EH 3_2015

Seitenübersicht